论文部分内容阅读
随着基因技术的发展,基因重组人红细胞生成素(rHuEPO)开始应用于临床,从而使慢性肾衰竭(CRF)患者的贫血得到了有效的治疗,避免了因输血带来的诸多弊端。随着rHuEPO在临床的推广使用,越来越多的医师开始关注与之相关的各种问题。请详阅第6版《专家访谈》。 2002年8月12～26日,中华医学会和中华国际医学交流基金会共同组织了“2002中华医学科普西部行”活动。专家组由中华医学会党组书记、副会长、秘书长宗淑杰教授带队,在宁夏回族自治区银川市的2所医院和新疆维吾尔族自治区的6所医院开展门诊14次,诊治患者200余人;查房24次(患者304人);讨论疑难病例23次(患者136人);召开座谈会1次,参加医生15人;进行手术41次;7位专家还做了40个专题学术报告,约10000人次的医生参加了培训。文详见第3版《学会动态》。
With the development of gene technology, recombinant human erythropoietin (rHuEPO) has been used clinically to effectively treat anemia in patients with chronic renal failure (CRF) and to avoid many drawbacks caused by blood transfusion. With the widespread use of rHuEPO in the clinic, more and more physicians are beginning to pay attention to various problems related to them. Please refer to the sixth edition of “expert interviews.” From August 12 to August 26, 2002, the Chinese Medical Association and the China International Medical Exchange Foundation jointly organized the “2002 China Medical Science Popularization”. The expert group led by the secretary of the Chinese Medical Association party group, Professor Zong Shujie, secretary general, led by two hospitals in Yinchuan City, Ningxia Hui Autonomous Region and six hospitals in Xinjiang Uygur Autonomous Region carried out 14 outpatient visits, diagnosed more than 200 patients ; Rounds of 24 rounds (304 patients); difficult cases to discuss 23 times (136 patients); held a forum to participate in 15 doctors; surgery 41 times; 7 experts also made 40 special academic reports, About 10,000 people attended the training of doctors. For more information, see the 3rd edition “Learning Dynamics.”